翰宇药业：翰宇药业龙华总部研发中心实验室“零缺陷”通过FDA检查

Core Viewpoint - Hanyu Pharmaceutical has successfully passed FDA inspections for its laboratories and production facilities, indicating strong compliance and operational capabilities in the pharmaceutical industry [1] Group 1 - Hanyu Pharmaceutical's Longhua headquarters R&D center laboratory achieved "zero defects" in FDA inspection on December 5, 2025, marking the second "zero defects" inspection success in 2023 [1] - The company's Wuhan raw material drug production base also passed the FDA inspection with "zero defects" on November 29, 2024 [1] - Hanyu Pharmaceutical's total production capacity for peptide raw materials exceeds 5 tons [1]